Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NewAmsterdam Pharma Company N.V. Warrant (NAMSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: NAMSW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -30.55% | Avg. Invested days 23 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.03 | 52 Weeks Range 5.45 - 16.75 | Updated Date 05/17/2025 |
52 Weeks Range 5.45 - 16.75 | Updated Date 05/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2314.47% |
Management Effectiveness
Return on Assets (TTM) -18.15% | Return on Equity (TTM) -31.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 54899238 |
Shares Outstanding - | Shares Floating 54899238 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NewAmsterdam Pharma Company N.V. Warrant
Company Overview
History and Background
NewAmsterdam Pharma, founded in 2019, is a clinical-stage biopharmaceutical company focused on the research and development of transformative therapies for cardio-metabolic diseases. They merged with Frazier Lifesciences Acquisition Corporation in 2022 to become publicly traded. This analysis focuses on the warrant (symbol unknown as it changes after the merger).
Core Business Areas
- Lipid Metabolism Therapies: Focuses on developing oral, once-daily therapies to improve lipid metabolism and address cardiovascular disease.
Leadership and Structure
Information on specific warrant leadership is unavailable separately from the merged entity. Focus is on the leadership of NewAmsterdam Pharma.
Top Products and Market Share
Key Offerings
- Obicetrapib: An investigational cholesteryl ester transfer protein (CETP) inhibitor. This drug focuses on reducing LDL-C and cardiovascular risk. It's currently in clinical trials. Competitors in the lipid-lowering space include statins (e.g., Lipitor, Crestor) and PCSK9 inhibitors (e.g., Repatha, Praluent). Market share data for Obicetrapib is not yet available due to its investigational status.
Market Dynamics
Industry Overview
The cardio-metabolic disease market is large and growing, driven by increasing prevalence of obesity, diabetes, and cardiovascular disease. There is significant unmet need for novel therapies to address these conditions.
Positioning
NewAmsterdam Pharma is positioned as a developer of novel lipid-lowering therapies, specifically targeting CETP inhibition. This approach is distinct from traditional statin therapy and offers potential for improved efficacy and tolerability.
Total Addressable Market (TAM)
The global cardiovascular disease market is estimated to be worth hundreds of billions of dollars. NewAmsterdam Pharma is positioned to capture a portion of this TAM with successful development and commercialization of Obicetrapib.
Upturn SWOT Analysis
Strengths
- Novel CETP inhibitor mechanism
- Strong clinical trial results for Obicetrapib
- Experienced management team
- Focus on a large and growing market
Weaknesses
- Obicetrapib still in clinical development
- Reliance on a single product candidate
- Potential for competition from other lipid-lowering therapies
Opportunities
- Expansion of Obicetrapib into new indications
- Partnerships with pharmaceutical companies
- Acquisition of other cardio-metabolic assets
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from generic statins and other lipid-lowering therapies
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- AMGN
- MRK
- PFE
- BMY
Competitive Landscape
NewAmsterdam Pharma faces significant competition from established pharmaceutical companies with existing lipid-lowering therapies. Its competitive advantage lies in its novel CETP inhibitor mechanism and potentially improved efficacy and tolerability.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by clinical trial progress and merger activities rather than revenue generation.
Future Projections: Future growth depends heavily on the successful development and commercialization of Obicetrapib. Analyst estimates are positive but subject to clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing Obicetrapib through clinical trials and preparing for potential regulatory submissions.
Summary
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company with a promising lead candidate, Obicetrapib, targeting cardio-metabolic diseases. The company's success hinges on positive clinical trial results and successful commercialization. It faces competition from established pharmaceutical giants and regulatory hurdles. The company is in a high-risk, high-reward position, and its future depends on advancing its clinical pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investment decisions should be made based on individual circumstances and after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NewAmsterdam Pharma Company N.V. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-11-23 | CEO, President, Executive Board Member & Director Dr. Michael Harvey Davidson FACC, Facp., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 77 | |
Full time employees 77 | |||
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.